two-sided wald chi-squared test Search Results


two-sided wald chi-squared test  (CH Instruments)
90
CH Instruments two-sided wald chi-squared test
Forest plot depicting the logistic regression multivariate analysis for the appearance of Neo RAS WT mCRC in Group A (4a) and Group B (4b). The adjusted odds ratio (OR: blue plot) and 95% confidence interval (CI: black horizontal lines) are shown for each factor. Various clinical factors and their association with the appearance of Neo RAS WT mCRC, as indicated by OR, are analyzed across the cohort using the two-sided <t>Wald</t> chi-squared test. The unadjusted OR of the appearance of Neo RAS WT mCRC is calculated as X/Y. For instance, about liver metastasis, X is defined as “the proportion of mCRC with liver metastases that became Neo RAS WT mCRC,” and Y is defined as “the proportion of mCRC without liver metastases that became Neo RAS WT mCRC.” An adjusted OR is an OR that has been adjusted to account for other predictor variables in the model (adjusted OR: 0.18, 95% CI: 0.09–0.34, P = 1.43 × 10 −7 ). Vertical dotted line: the null hypothesis. Number of events: Group A = 91; Group B = 42. Source data are provided as a Source Data file. mCRC metastatic colorectal cancer, WT wild-type, RAS rat sarcoma viral oncogene homolog, VEGF vascular endothelial growth factor.
Two Sided Wald Chi Squared Test, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/two-sided+wald+chi-squared+test/pmc11246505-82-26-27?v=CH+Instruments
Average 90 stars, based on 1 article reviews
two-sided wald chi-squared test - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
wald chi square test results  (CH Instruments)
90
CH Instruments wald chi square test results
Forest plot depicting the logistic regression multivariate analysis for the appearance of Neo RAS WT mCRC in Group A (4a) and Group B (4b). The adjusted odds ratio (OR: blue plot) and 95% confidence interval (CI: black horizontal lines) are shown for each factor. Various clinical factors and their association with the appearance of Neo RAS WT mCRC, as indicated by OR, are analyzed across the cohort using the two-sided <t>Wald</t> chi-squared test. The unadjusted OR of the appearance of Neo RAS WT mCRC is calculated as X/Y. For instance, about liver metastasis, X is defined as “the proportion of mCRC with liver metastases that became Neo RAS WT mCRC,” and Y is defined as “the proportion of mCRC without liver metastases that became Neo RAS WT mCRC.” An adjusted OR is an OR that has been adjusted to account for other predictor variables in the model (adjusted OR: 0.18, 95% CI: 0.09–0.34, P = 1.43 × 10 −7 ). Vertical dotted line: the null hypothesis. Number of events: Group A = 91; Group B = 42. Source data are provided as a Source Data file. mCRC metastatic colorectal cancer, WT wild-type, RAS rat sarcoma viral oncogene homolog, VEGF vascular endothelial growth factor.
Wald Chi Square Test Results, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/two-sided+wald+chi-squared+test/pmc06223739-38-0-4?v=CH+Instruments
Average 90 stars, based on 1 article reviews
wald chi square test results - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
chi-squared  (CH Instruments)
90
CH Instruments chi-squared
Forest plot depicting the logistic regression multivariate analysis for the appearance of Neo RAS WT mCRC in Group A (4a) and Group B (4b). The adjusted odds ratio (OR: blue plot) and 95% confidence interval (CI: black horizontal lines) are shown for each factor. Various clinical factors and their association with the appearance of Neo RAS WT mCRC, as indicated by OR, are analyzed across the cohort using the two-sided <t>Wald</t> chi-squared test. The unadjusted OR of the appearance of Neo RAS WT mCRC is calculated as X/Y. For instance, about liver metastasis, X is defined as “the proportion of mCRC with liver metastases that became Neo RAS WT mCRC,” and Y is defined as “the proportion of mCRC without liver metastases that became Neo RAS WT mCRC.” An adjusted OR is an OR that has been adjusted to account for other predictor variables in the model (adjusted OR: 0.18, 95% CI: 0.09–0.34, P = 1.43 × 10 −7 ). Vertical dotted line: the null hypothesis. Number of events: Group A = 91; Group B = 42. Source data are provided as a Source Data file. mCRC metastatic colorectal cancer, WT wild-type, RAS rat sarcoma viral oncogene homolog, VEGF vascular endothelial growth factor.
Chi Squared, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/two-sided+wald+chi-squared+test/pmc06299523-73-2-4?v=CH+Instruments
Average 90 stars, based on 1 article reviews
chi-squared - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
two-sided chi-squared test  (CH Instruments)
90
CH Instruments two-sided chi-squared test
Forest plot depicting the logistic regression multivariate analysis for the appearance of Neo RAS WT mCRC in Group A (4a) and Group B (4b). The adjusted odds ratio (OR: blue plot) and 95% confidence interval (CI: black horizontal lines) are shown for each factor. Various clinical factors and their association with the appearance of Neo RAS WT mCRC, as indicated by OR, are analyzed across the cohort using the two-sided <t>Wald</t> chi-squared test. The unadjusted OR of the appearance of Neo RAS WT mCRC is calculated as X/Y. For instance, about liver metastasis, X is defined as “the proportion of mCRC with liver metastases that became Neo RAS WT mCRC,” and Y is defined as “the proportion of mCRC without liver metastases that became Neo RAS WT mCRC.” An adjusted OR is an OR that has been adjusted to account for other predictor variables in the model (adjusted OR: 0.18, 95% CI: 0.09–0.34, P = 1.43 × 10 −7 ). Vertical dotted line: the null hypothesis. Number of events: Group A = 91; Group B = 42. Source data are provided as a Source Data file. mCRC metastatic colorectal cancer, WT wild-type, RAS rat sarcoma viral oncogene homolog, VEGF vascular endothelial growth factor.
Two Sided Chi Squared Test, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/two-sided+wald+chi-squared+test/pm27587543-127-2-2?v=CH+Instruments
Average 90 stars, based on 1 article reviews
two-sided chi-squared test - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
chi-square test  (CH Instruments)
90
CH Instruments chi-square test
Forest plot depicting the logistic regression multivariate analysis for the appearance of Neo RAS WT mCRC in Group A (4a) and Group B (4b). The adjusted odds ratio (OR: blue plot) and 95% confidence interval (CI: black horizontal lines) are shown for each factor. Various clinical factors and their association with the appearance of Neo RAS WT mCRC, as indicated by OR, are analyzed across the cohort using the two-sided <t>Wald</t> chi-squared test. The unadjusted OR of the appearance of Neo RAS WT mCRC is calculated as X/Y. For instance, about liver metastasis, X is defined as “the proportion of mCRC with liver metastases that became Neo RAS WT mCRC,” and Y is defined as “the proportion of mCRC without liver metastases that became Neo RAS WT mCRC.” An adjusted OR is an OR that has been adjusted to account for other predictor variables in the model (adjusted OR: 0.18, 95% CI: 0.09–0.34, P = 1.43 × 10 −7 ). Vertical dotted line: the null hypothesis. Number of events: Group A = 91; Group B = 42. Source data are provided as a Source Data file. mCRC metastatic colorectal cancer, WT wild-type, RAS rat sarcoma viral oncogene homolog, VEGF vascular endothelial growth factor.
Chi Square Test, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/two-sided+wald+chi-squared+test/pmc03644693-43-33-33?v=CH+Instruments
Average 90 stars, based on 1 article reviews
chi-square test - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
monoclonal antibody ms#13  (CH Instruments)
90
CH Instruments monoclonal antibody ms#13
Forest plot depicting the logistic regression multivariate analysis for the appearance of Neo RAS WT mCRC in Group A (4a) and Group B (4b). The adjusted odds ratio (OR: blue plot) and 95% confidence interval (CI: black horizontal lines) are shown for each factor. Various clinical factors and their association with the appearance of Neo RAS WT mCRC, as indicated by OR, are analyzed across the cohort using the two-sided <t>Wald</t> chi-squared test. The unadjusted OR of the appearance of Neo RAS WT mCRC is calculated as X/Y. For instance, about liver metastasis, X is defined as “the proportion of mCRC with liver metastases that became Neo RAS WT mCRC,” and Y is defined as “the proportion of mCRC without liver metastases that became Neo RAS WT mCRC.” An adjusted OR is an OR that has been adjusted to account for other predictor variables in the model (adjusted OR: 0.18, 95% CI: 0.09–0.34, P = 1.43 × 10 −7 ). Vertical dotted line: the null hypothesis. Number of events: Group A = 91; Group B = 42. Source data are provided as a Source Data file. mCRC metastatic colorectal cancer, WT wild-type, RAS rat sarcoma viral oncogene homolog, VEGF vascular endothelial growth factor.
Monoclonal Antibody Ms#13, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/two-sided+wald+chi-squared+test/pmc09700799-88-5-40?v=CH+Instruments
Average 90 stars, based on 1 article reviews
monoclonal antibody ms#13 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
apc model  (STATA Corporation)
99
STATA Corporation apc model
Forest plot depicting the logistic regression multivariate analysis for the appearance of Neo RAS WT mCRC in Group A (4a) and Group B (4b). The adjusted odds ratio (OR: blue plot) and 95% confidence interval (CI: black horizontal lines) are shown for each factor. Various clinical factors and their association with the appearance of Neo RAS WT mCRC, as indicated by OR, are analyzed across the cohort using the two-sided <t>Wald</t> chi-squared test. The unadjusted OR of the appearance of Neo RAS WT mCRC is calculated as X/Y. For instance, about liver metastasis, X is defined as “the proportion of mCRC with liver metastases that became Neo RAS WT mCRC,” and Y is defined as “the proportion of mCRC without liver metastases that became Neo RAS WT mCRC.” An adjusted OR is an OR that has been adjusted to account for other predictor variables in the model (adjusted OR: 0.18, 95% CI: 0.09–0.34, P = 1.43 × 10 −7 ). Vertical dotted line: the null hypothesis. Number of events: Group A = 91; Group B = 42. Source data are provided as a Source Data file. mCRC metastatic colorectal cancer, WT wild-type, RAS rat sarcoma viral oncogene homolog, VEGF vascular endothelial growth factor.
Apc Model, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/two-sided+wald+chi-squared+test/pmc11738906-110-3-8?v=STATA+Corporation
Average 99 stars, based on 1 article reviews
apc model - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier

Image Search Results


Forest plot depicting the logistic regression multivariate analysis for the appearance of Neo RAS WT mCRC in Group A (4a) and Group B (4b). The adjusted odds ratio (OR: blue plot) and 95% confidence interval (CI: black horizontal lines) are shown for each factor. Various clinical factors and their association with the appearance of Neo RAS WT mCRC, as indicated by OR, are analyzed across the cohort using the two-sided Wald chi-squared test. The unadjusted OR of the appearance of Neo RAS WT mCRC is calculated as X/Y. For instance, about liver metastasis, X is defined as “the proportion of mCRC with liver metastases that became Neo RAS WT mCRC,” and Y is defined as “the proportion of mCRC without liver metastases that became Neo RAS WT mCRC.” An adjusted OR is an OR that has been adjusted to account for other predictor variables in the model (adjusted OR: 0.18, 95% CI: 0.09–0.34, P = 1.43 × 10 −7 ). Vertical dotted line: the null hypothesis. Number of events: Group A = 91; Group B = 42. Source data are provided as a Source Data file. mCRC metastatic colorectal cancer, WT wild-type, RAS rat sarcoma viral oncogene homolog, VEGF vascular endothelial growth factor.

Journal: Nature Communications

Article Title: Clinical features associated with Neo RAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy

doi: 10.1038/s41467-024-50026-4

Figure Lengend Snippet: Forest plot depicting the logistic regression multivariate analysis for the appearance of Neo RAS WT mCRC in Group A (4a) and Group B (4b). The adjusted odds ratio (OR: blue plot) and 95% confidence interval (CI: black horizontal lines) are shown for each factor. Various clinical factors and their association with the appearance of Neo RAS WT mCRC, as indicated by OR, are analyzed across the cohort using the two-sided Wald chi-squared test. The unadjusted OR of the appearance of Neo RAS WT mCRC is calculated as X/Y. For instance, about liver metastasis, X is defined as “the proportion of mCRC with liver metastases that became Neo RAS WT mCRC,” and Y is defined as “the proportion of mCRC without liver metastases that became Neo RAS WT mCRC.” An adjusted OR is an OR that has been adjusted to account for other predictor variables in the model (adjusted OR: 0.18, 95% CI: 0.09–0.34, P = 1.43 × 10 −7 ). Vertical dotted line: the null hypothesis. Number of events: Group A = 91; Group B = 42. Source data are provided as a Source Data file. mCRC metastatic colorectal cancer, WT wild-type, RAS rat sarcoma viral oncogene homolog, VEGF vascular endothelial growth factor.

Article Snippet: Various clinical factors and their association with the appearance of Neo RAS WT mCRC, as indicated by OR, are analyzed across the cohort using the two-sided Wald chi-squared test.

Techniques: